Elin Rosendahl Email

Chief Development Officer (CDO) . AnaCardio

Current Roles

Employees:
28
Revenue:
$5.6M
About
AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022. You can find more information about AnaCardio at www.anacardio.com.
AnaCardio Address

Solna, null
SE
AnaCardio Email